Co-Delivery of Loxoprofen and Tofacitinib by Photothermal Microneedles for Rheumatoid Arthritis Treatment
Pharmaceutics · 15.05.2023 · 15 (5) · 1500
DOI: 10.3390/pharmaceutics15051500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 15.05.2023. Verfasst von Yi Lu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is an autoimmune disease of synovial inflammation that affects populations worldwide. Transdermal drug delivery systems for treating RA have increased but remain challenging. We fabricated a dissolving microneedle (MN) system with photothermal (PT) polydopamine (PDA) to co-load the non-steroidal anti-inflammatory drug loxoprofen (Lox) and the Janus kinase inhibitor tofacitinib (Tof), with the aim of co-delivering Lox and Tof directly to the articular cavity, aided by the combination of MN and PT. In vitro and in vivo permeation studies showed that the PT MN significantly promoted drug permeation and retention in the skin. An in vivo visualization of the drug distribution in the articular cavity showed that the PT MN significantly promoted drug retention in the articular cavity. Importantly, compared to the intra-articular injection of Lox and Tof, the application of the PT MN to a carrageenan/kaolin-induced arthritis rat model exhibited superior performance in reducing joint swelling, muscle atrophy, and cartilage destruction. Furthermore, the PT MN downregulated the mRNA expression levels of proinflammatory cytokines, including TNF-α, IL-1β, iNOS, JAK2, JAK3, and STAT3. The results show that the PT MN transdermal co-delivery of Lox and Tof is a new synergetic therapy with high compliance and good therapeutic efficacy for RA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
- State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
- Department of Dermatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
- Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
ORCID-Profile: Guihong Chai, Jinjing Jia
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Lu, Y., Xiao, T., Lai, R., Liu, Z., Luo, W., Wang, Y., Fu, S., Chai, G., Jia, J., & Xu, Y. (2023). Co-Delivery of Loxoprofen and Tofacitinib by Photothermal Microneedles for Rheumatoid Arthritis Treatment. Pharmaceutics, 15(5), 1500. https://doi.org/10.3390/pharmaceutics15051500
Vancouver
Lu Y, Xiao T, Lai R, Liu Z, Luo W, Wang Y, et al. Co-Delivery of Loxoprofen and Tofacitinib by Photothermal Microneedles for Rheumatoid Arthritis Treatment. Pharmaceutics. 2023;15(5):1500. doi:10.3390/pharmaceutics15051500
BibTeX
@article{Lu2023,
author = {Lu, Yi and Xiao, Ting and Lai, Rongrong and Liu, Ziyi and Luo, Weixuan and Wang, Yixuan and Fu, Shijia and Chai, Guihong and Jia, Jinjing and Xu, Yuehong},
title = {Co-Delivery of Loxoprofen and Tofacitinib by Photothermal Microneedles for Rheumatoid Arthritis Treatment},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {5},
pages = {1500},
doi = {10.3390/pharmaceutics15051500}
}
EUVIMED